Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brexit

Set Alert for Brexit

‘Keep Planning For No-Deal Brexit,’ UK Govt Tells Pharma As Chaos Grows

Amid the growing mayhem in parliament over the Brexit process, life science companies have been advised to continue preparing for the possibility that the UK might leave the EU without a deal at the end of next week. 
United Kingdom Brexit Trade

UK Drug Pricing & IP Targeted As US Gears Up For Post-Brexit Trade Deal Talks

The US has published its final negotiating objectives for a post-Brexit trade deal with the UK, which include pushing for stronger IP protections and changes to UK processes for patient access to new drugs.

United Kingdom United States Brexit

Latest From Brexit

Pharma Told To Maintain Drug Stockpiles Despite Six-Month Brexit Delay

An agreement to delay Brexit has brought no reprieve for the pharmaceutical sector, which must remain at a heightened state of preparedness as a no-deal scenario is still a possibility. Industry says it will seek clarity on the practical implications of this.
Europe United Kingdom

Brexit Delay Gives EU27 Yet More Time To Grow Number Of EU-Compliant Devices

Has the European Commission done enough to allow UK-certified medical devices to continue on the EU27 market in the event of the UK dropping out of the EU without a deal – a possibility that remains very real?

Brexit EU

Further Brexit Delay Avoids No-Deal Impact For Pharma – For Now

The EU has given the UK another extension, this time until 31 October, to find a solution to the Brexit impasse. In the meantime, things will stay pretty much as they are for the life sciences sector, although the possibility of a no-deal exit remains if a withdrawal agreement cannot be ratified. 
Brexit Regulation

EU MDR: Any Surprises In The European Commission Notified Body Database?

How many notified bodies have been designated under the new EU Medical Device and IVD Regulations? Medtech Insight looks at the Nando database to monitor developments.

EU Regulation

Expert View: No-Deal Brexit's Legal Fallout For Pharma

Dr Jonathan Atkinson, partner at the UK-based intellectual property law firm HGF Ltd, sums up key expectations around legal, patent-related and trademark aspects for pharma in the event of a "no-deal" Brexit, and highlights regulatory changes that could have a bearing on the deal value of UK-bound M&A activity.

Legal Issues Brexit

EU Regulatory Roundup, March 2019: Lots More MDR/IVDR News, And Top Ten Summary

March 2019 was a busy month in terms of news for those preparing for the implementation of the MDR and IVDR, while Brexit negotiations spiraled into a new level of madness.

EU United Kingdom

Scottish Govt Explains Approach To No-Deal Brexit Drug Shortages

The chief medical and pharmaceutical officers of Scotland have outlined steps being taken to mitigate potential drug shortages if the UK leaves the EU without a deal. Meanwhile, a judge has dismissed a legal challenge to the UK government’s proposal allowing pharmacists to change a doctor’s prescription in the event of a serious medicine shortage.

Brexit United Kingdom

EU No-Deal Scenario Looms Still, But MHRA’s Reg Oversight Of UK Medtech On Hold

UK parliament’s indecision over how – or if – to enact Brexit saw the planned March 29 withdrawal deadline come and go. The default positions of the inter-ministerial Office for Lifesciences (OLS) and health-care products regulator (MHRA) are still to prepare for a no-deal exit from the EU.

United Kingdom Brexit

What Now After Brexit Delay? UK BioIndustry Association Asks

Steve Bates, CEO of the UK BioIndustry Association, tries to untangle the increasingly chaotic Brexit process and establish how the various scenarios might pan out for the life sciences industry.
United Kingdom Brexit
See All
Advertisement
UsernamePublicRestriction

Register